We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

MPOD in Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin (MacTEL-Supp)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2007 by The Lowy Medical Research Institute Limited.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00568828
First Posted: December 6, 2007
Last Update Posted: December 6, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
The Lowy Medical Research Institute Limited
  Purpose

Earlier investigations have detected low levels of macular pigment (MP) in the center of the fovea and a halo of MP at a higher eccentricity in persons with type 2 idiopathic juxtafoveal teleangiectasia (MACTEL)[Helb H-M, Charbel Issa P, Pauleikhoff D, Scholl HPN, Holz FG, MacTel-Study Group. Macular Pigment Density and Distribution in Patients with Macular Telangiectasia. ARVO Annual Meeting 2006, Fort Lauderdale, 30.04.-5.05.2006. Program # 5701/B795]. To date it is not known whether the total MP is reduced in MACTEL or whether even more MP accumulates at higher eccenticities compared to healthy probands. With the suggested study we aim to

  1. investigate Lutein and Zeaxanthin serum levels in MACTEL probands
  2. investigate and quantify MP at the posterior pole of MACTEL probands
  3. detect possible changes of MP concentration and distribution following supplementation with Lutein and Zeaxanthin

Condition
Macular Teleangiectasia Macular Pigment

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pilot Study to Evaluate the Changes of Macular Pigment Optical Density in Patients With Idiopathic Macular Teleangiectasia Following Supplementation of Lutein and Zeaxanthin

Further study details as provided by The Lowy Medical Research Institute Limited:

Primary Outcome Measures:
  • Macular Pigment Optical Density [ Time Frame: 3 months ]

Estimated Enrollment: 12
Study Start Date: December 2007
Estimated Study Completion Date: February 2008
  Show Detailed Description

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
12 patients with Macular Teleangiectasia
Criteria

Inclusion Criteria:

  • Different distribution of macular pigment in patients with known macular teleangiectasia

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00568828


Contacts
Contact: Daniel Pauleikhoff, MD 49-251-933080 dapauleikhoff@muenster.de

Locations
Germany
Dep. of Ophthalmology, St. Franziskus Hospital Recruiting
Muenster, Germany, 48145
Contact: Meike Zeimer, MD    49-251-933080    kpl-auge@muenster.de   
Sponsors and Collaborators
The Lowy Medical Research Institute Limited
Investigators
Principal Investigator: Daniel Pauleikhoff, MD Chairman Dep. of Ophthalmology, St.Franziskus Hospital, Muenster, Germany
  More Information

Responsible Party: Daniel Pauleikhoff MD, Dep. of Ophthalmology, St. Franziskus Hospital, Muenster, Germany
ClinicalTrials.gov Identifier: NCT00568828     History of Changes
Other Study ID Numbers: MacTEL Supplement
First Submitted: December 5, 2007
First Posted: December 6, 2007
Last Update Posted: December 6, 2007
Last Verified: December 2007

Keywords provided by The Lowy Medical Research Institute Limited:
Macular Teleangiectasia
Macular Pigment